Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Burger

Showing results (121-130 of 337) with videos related to

Pageof 34
Sort By:
AIDS (London, England)|May 2, 2012
Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatmentJ Mirjam Oudijk, Helen McIlleron, Veronica Mulenga, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 19, 2008
Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected childrenTim R Cressey, Hannah Green, Saye Khoo, et al.
Antiviral Therapy|September 17, 2015
Pharmacokinetic drug-drug interaction study between raltegravir and citalopramMaren I Blonk, Charlotte Ca Langemeijer, Angela Ph Colbers, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|January 29, 2017
Dried Blood Spot sampling in psychiatry: Perspectives for improving therapeutic drug monitoringLisa C Martial, Rob E Aarnoutse, Martina Mulder, et al.
Clinical Pharmacokinetics|November 7, 2024
Drug-Drug Interaction Management with the Novel Anti-Cytomegalovirus Agents Letermovir and Maribavir: Guidance for CliniciansDavid M Burger, Laura Nijboer, Mira Ghobreyal, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 21, 2021
Point-of-Care Detection of Nonadherence to Antiretroviral Treatment for HIV-1 in Resource-Limited Settings Using Drug Level Testing for Efavirenz, Lopinavir, and Dolutegravir: A Validation and Pharmacokinetic Simulation StudyLucas E Hermans, Monique Nijhuis, Hugo A Tempelman, et al.
Clinical Pharmacokinetics|May 2, 2024
Correction: Relative Bioavailability of Dolutegravir (DTG) and Emtricitabine/Tenofovir Alafenamide Fumarate (F/TAF) Administered as Paediatric Tablet Formulations in Healthy VolunteersLisanne A H Bevers, Anne E M Kamphuis, L C Wendy van der Wekken-Pas, et al.
Drug Safety|April 22, 2016
Pharmacokinetics, Efficacy, and Safety of Hepatitis C Virus Drugs in Patients with Liver and/or Renal ImpairmentElise J Smolders, Clara T M M de Kanter, Bart van Hoek, et al.
Therapeutic Drug Monitoring|September 28, 2002
Therapeutic drug monitoring of HIV-protease inhibitors to assess noncompliancePatricia W H Hugen, David M Burger, Rob E Aarnoutse, et al.
Antimicrobial Agents and Chemotherapy|May 2, 2018
Pharmacokinetics of Anidulafungin in Obese and Normal-Weight AdultsRoeland E Wasmann, Rob Ter Heine, Eric P van Dongen, et al.
Pageof 34

Showing results (121-130 of 337) with videos related to

Sort By:
Pageof 34
AIDS (London, England)|May 2, 2012
Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatmentJ Mirjam Oudijk, Helen McIlleron, Veronica Mulenga, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 19, 2008
Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected childrenTim R Cressey, Hannah Green, Saye Khoo, et al.
Antiviral Therapy|September 17, 2015
Pharmacokinetic drug-drug interaction study between raltegravir and citalopramMaren I Blonk, Charlotte Ca Langemeijer, Angela Ph Colbers, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|January 29, 2017
Dried Blood Spot sampling in psychiatry: Perspectives for improving therapeutic drug monitoringLisa C Martial, Rob E Aarnoutse, Martina Mulder, et al.
Clinical Pharmacokinetics|November 7, 2024
Drug-Drug Interaction Management with the Novel Anti-Cytomegalovirus Agents Letermovir and Maribavir: Guidance for CliniciansDavid M Burger, Laura Nijboer, Mira Ghobreyal, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 21, 2021
Point-of-Care Detection of Nonadherence to Antiretroviral Treatment for HIV-1 in Resource-Limited Settings Using Drug Level Testing for Efavirenz, Lopinavir, and Dolutegravir: A Validation and Pharmacokinetic Simulation StudyLucas E Hermans, Monique Nijhuis, Hugo A Tempelman, et al.
Clinical Pharmacokinetics|May 2, 2024
Correction: Relative Bioavailability of Dolutegravir (DTG) and Emtricitabine/Tenofovir Alafenamide Fumarate (F/TAF) Administered as Paediatric Tablet Formulations in Healthy VolunteersLisanne A H Bevers, Anne E M Kamphuis, L C Wendy van der Wekken-Pas, et al.
Drug Safety|April 22, 2016
Pharmacokinetics, Efficacy, and Safety of Hepatitis C Virus Drugs in Patients with Liver and/or Renal ImpairmentElise J Smolders, Clara T M M de Kanter, Bart van Hoek, et al.
Therapeutic Drug Monitoring|September 28, 2002
Therapeutic drug monitoring of HIV-protease inhibitors to assess noncompliancePatricia W H Hugen, David M Burger, Rob E Aarnoutse, et al.
Antimicrobial Agents and Chemotherapy|May 2, 2018
Pharmacokinetics of Anidulafungin in Obese and Normal-Weight AdultsRoeland E Wasmann, Rob Ter Heine, Eric P van Dongen, et al.
Pageof 34